Stallergenes Greer announced that the company has entered into an exclusive partnership with Aptar Pharma for the development of the first of its kind connected device and companion mobile app for patients undergoing Stallergenes Greer?s AIT treatments with sublingual solutions. Non-adherence to an AIT schedule and premature discontinuation of treatment remain a challenge in AIT management. This innovative, easy-to-use connected device will contribute to improving dose compliance and adherence, thus optimising treatment outcomes. The development work is being undertaken by Aptar Pharma?s Digital Health group, which has capabilities and expertise in device and software development. The product will leverage Aptar Pharma?s Cohero platform, which will be tailored specifically for this use. The newly developed connected device should be available in France in 2022 and will be progressively rolled-out in Stallergenes Greer?s markets. This innovation further illustrates Stallergenes Greer?s commitment to build on precision medicine and personalised healthcare which cater to the needs of both patients and the medical community.